IP Library › Granted Patent US 12,428,449
Granted Patent B2
US 12,428,449 · App. 18/655,708 · Granted Sep 30, 2025

FimH mutant, compositions therewith and use thereof

Inventors: Jan Grijpstra (Beesd, NL); Eveline Marleen Weerdenburg (Uithoorn, NL); Jeroen Geurtsen (Vleuten, NL); Kellen Cristhina Fae (Mainz, DE); Louris Jakob Feitsma (Utrecht, NL)
Assignee: Janssen Pharmaceuticals, Inc.
C07K14/195A61K39/025A61K39/0258C07K14/245C07K16/1232
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,449
App. No.
18/655,708
Granted
Sep 30, 2025
Kind
B2
Abstract

Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.

Claims (4)

1. A method of inducing antibodies against a wild-type FimH polypeptide in a mammalian subject in need thereof, the method comprising administering to the subject an effective amount of a polynucleotide encoding a polypeptide comprising a FimH lectin domain, wherein the FimH lectin domain comprises valine at the position corresponding to position 144 of SEQ ID NO: 1; or a pharmaceutical composition comprising said polynucleotide, wherein the antibodies are capable of blocking adhesion of Escherichia coli cells to bladder epithelial cells.

2. The method of claim 1 , wherein the mammalian subject is in need of treatment or prevention of urinary tract infection (UTI) due to E. coli , or suppressing symptoms and/or sequelae associated with the UTI.

3. The method of claim 1 , wherein said mammalian subject is a human.

4. The method of claim 2 , wherein said mammalian subject is a human.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2024
From: GRIJPSTRA, JAN; WEERDENBURG, MARLEEN EVELINE; GEURTSEN, JEROEN; FAE, KELLEN CRISTHINA; FEITSMA, JAKOB LOURIS
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 067944/0189 →
Priority Claims (1)
EP 20152217 · Jan 16, 2020 · regional
Continuity (3)
Division 17814966 · Jul 26, 2022
Division 17150025 · Jan 15, 2021
Related Publication 20240294582A1 · Sep 5, 2024
References Cited (134)
US 4436727A · Ribi · 1984 [cited by applicant]
US 4866034A · Ribi · 1989 [cited by applicant]
US 4877611A · Cantrell · 1989 [cited by applicant]
US 4912094A · Myers · 1990 [cited by applicant]
US 4987237A · Myers · 1991 [cited by applicant]
US 5057540A · Kensil · 1991 [cited by applicant]
US 5191072A · Hasegawa · 1993 [cited by applicant]
US 5370872A · Cryz · 1994 [cited by applicant]
US 5593969A · Kamireddy · 1997 [cited by applicant]
US 5750110A · Prieels · 1998 [cited by applicant]
US 6299884B1 · Van Nest · 2001 [cited by applicant]
US 6451325B1 · Van Nest · 2002 [cited by applicant]
US 6491919B2 · Crane · 2002 [cited by applicant]
US 6500434B1 · Langermann · 2002 [cited by applicant]
US 6676958B2 · Gerber · 2004 [cited by applicant]
US 6737063B2 · Langermann · 2004 [cited by applicant]
US 6759241B1 · Hone · 2004 [cited by applicant]
US 7357936B1 · Garcon · 2008 [cited by applicant]
US 8168195B2 · Szu · 2012 [cited by applicant]
US 8722064B2 · Reed · 2014 [cited by applicant]
US 9017698B2 · Eldridge · 2015 [cited by applicant]
US 9149521B2 · Eldridge · 2015 [cited by applicant]
US 9149522B2 · Eldridge · 2015 [cited by applicant]
US 9415097B2 · Eldridge · 2016 [cited by applicant]
US 9415101B2 · Eldridge · 2016 [cited by applicant]
US 9504743B2 · Eldridge · 2016 [cited by applicant]
US 9700612B2 · Kowarik · 2017 [cited by applicant]
US 10441647B2 · Kowarik · 2019 [cited by applicant]
US 10456462B2 · Langedijk · 2019 [cited by applicant]
US 11229694B2 · Langedijk · 2022 [cited by applicant]
US 11421003B2 · Grijpstra · 2022 [cited by applicant]
US 11725028B2 · Grijpstra · 2023 [cited by applicant]
US 12012435B2 · Grijpstra · 2024 [cited by applicant]
US 20020150587A1 · Langermann · 2002 [cited by applicant]
US 20030138449A1 · Langermann · 2003 [cited by applicant]
US 20030199071A1 · Langermann · 2003 [cited by applicant]
US 20100310602A1 · Reed · 2010 [cited by applicant]
US 20110206758A1 · Vandepapeliere · 2011 [cited by applicant]
US 20150056224A1 · Dubensky, Jr. · 2015 [cited by applicant]
US 20150216969A1 · Eldridge · 2015 [cited by applicant]
US 20150238588A1 · Kowarik · 2015 [cited by applicant]
US 20190275135A1 · Poolman · 2019 [cited by applicant]
US 20210221856A1 · Grijpstra · 2021 [cited by applicant]
US 20220125912A1 · Langedijk · 2022 [cited by applicant]
US 20220220159A1 · Grijpstra · 2022 [cited by applicant]
EP 0399843 · 1990 [cited by applicant]
EP 0761231A1 · 1997 [cited by applicant]
EP 0671948B1 · 1997 [cited by applicant]
EP 0971739B1 · 2004 [cited by applicant]
EP 1126876B1 · 2007 [cited by applicant]
EP 1194166B1 · 2007 [cited by applicant]
EP 1385541B1 · 2008 [cited by applicant]
GB 2220211A · 1990 [cited by applicant]
WO 0204496A2 · 2002 [cited by applicant]
WO 2002102974 · 2002 [cited by applicant]
WO 2006116423A2 · 2006 [cited by applicant]
WO 2006119987A2 · 2006 [cited by applicant]
WO 2007109812A2 · 2007 [cited by applicant]
WO 2007109813A1 · 2007 [cited by applicant]
WO 2009104074A2 · 2009 [cited by applicant]
WO 2013119856A1 · 2013 [cited by applicant]
WO 2015124769A1 · 2015 [cited by applicant]
WO 2016183501 · 2016 [cited by applicant]
WO 2017035181A1 · 2017 [cited by applicant]
WO 2021123360A1 · 2021 [cited by applicant]
Starks et al., “Optimization and qualification of an assay that demonstrates that a FimH vaccine induces functional antibody responses in women with histories of urinary tract infections,” Human Vaccines & Immunotherape… [cited by applicant]
Edited by Yaming et al., “Medical Immunology,” Shanghai: Shanghai Science and Technology Press, Nov. 2016 (4 pages) described in CN Office Action dated Sep. 30, 2024 (NPL2). [cited by applicant]
English translation of CN Office Action dated Sep. 30, 2024 (4 pages). [cited by applicant]
Schembri et al., “Molecular characterization of the [cited by applicant]
Kalas et al., “Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions,” Sci Adv (2017) 3(2):e1601944 (14 pages). [cited by applicant]
Adjuvants—Immunotherapy & Vaccine Development, Avanti Polar Lipids, Inc., downloaded from web page: http://www.avantilipids.com/divisions/adjuvants, Download date: Sep. 11, 2019, original posting date: unknown, pp. 1-4. [cited by applicant]
Alving, Carl R., et al. “Adjuvants for Human Vaccines.” Curr Opin Immunol. Jun. 2021; 24(3):310-315. [cited by applicant]
Apicella et al, “Isolation and Characterization of Lipopolysaccharides, Lipoogliosaccharides, and Lipid A,” Methods n Enzymology, vol. 235, pp. 242-252 (1994). [cited by applicant]
Baliban et al, “Development of glycoconjugate vaccine to prevent invasive [cited by applicant]
Barnhart et al, “Chaperone-Subunit-Usher Interactions Required for Donor Strand Exchange during Bacterial Pilus Assembly,” Journal of Bacteriology, vol. 185, No. 9, pp. 2723-2730 (May 2003). [cited by applicant]
Barnhart et al, “PapD-like chaperones provide the missing information for folding of pilin proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, No. 14, pp. 7709-7714 (Jul.… [cited by applicant]
Boudeau et al, “Invasive Ability of an [cited by applicant]
Brumbaugh et al, “Preventing urinary tract infection: progress toward an effective [cited by applicant]
Carter, Darrick, et al. “A structure-function approach to optimizing TLR4 ligands for human vaccines.” Clinical & Translational Immunology 5.11 (2016): e108, pp. 1-8. [cited by applicant]
Choudhury et al, “X-ray structure of the FimC-FimH Chaperone-Adhesin Complex from Uropathogenic [cited by applicant]
Cryz et al, “Synthesis and characterization of a polyvalent [cited by applicant]
Desilets et al, “Genome-based Definition of an Inflammatory Bowel Disease-associated Adherent-Invasive [cited by applicant]
Fattom et al, “Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines,” Vaccine, vol. 17, pp. 126-133 (1999). [cited by applicant]
Ghosh Arunita et al: “Incidence of multidrug resistance, pathogenicity island markers, and pathoadaptive FimH mutations in uropathogenic [cited by applicant]
Greenspan et al., Defining epitopes: It's not as easy as it seems, Nature Biotechnology 17: 936-937, 1999. [cited by applicant]
Gregg, Kelsey, et al. “Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.” MBio 8.3 (2017): e00492-17, pp. 1-14. [cited by applicant]
Ho et al, “Preclinical Laboratory Evaluation of a Bivalent [cited by applicant]
Huttner et al, “Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic [cited by applicant]
Ihssen et al, “Production of glycoprotein vaccines in [cited by applicant]
Ireton, Gregory, et al. “Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.” Expert Review of Vaccines, vol. 12, pp. 793-807 (2013). [cited by applicant]
Johnson David A., et al. “3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities.” Journal of Medicinal Chemistry 42.22 (1999): 4640-4649. [cited by applicant]
Kensil et al, “Structural and Immunogical Characterization of the Vaccine Adjuvant QS-21,” Vaccine Design: The Subunit and Adjuvant Approach, pp. 525-541 (1995). [cited by applicant]
Kisiela et al. 2013 (Conformations inactivation induces immunogenicity of the receptor-binding pocket of a bacterial adhesion; PNAS 110 (47): 19089-19094) (Year: 2013), pp. 19089-19094. [cited by applicant]
Langermann et al, “Prevention of Mucosal [cited by applicant]
Langermann et al. 2000 (Vaccination with FimH adhesion Protects Cynomolgus Monkeys from Colonization and Infection by Uropathogenic [cited by applicant]
Lazar et al., Transforming Growth Factor alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cellular Biol. 8: 1247-1252, 1988. [cited by applicant]
Lukac et al, “Toxoid of Pseudomonas aeruginosa Exotoxin A Generated by Deletion of an Active-Site Residue,” Infection and Immunity, vol. 56, No. 12, pp. 3095-3098 (1988). [cited by applicant]
Martinez-Medina et al., “ [cited by applicant]
Masson et al, “Calcium phosphate: a substitute for aluminum adjuvants?” Expert Review of Vaccines, vol. 16, pp. 289-299 (2017). [cited by applicant]
Meloni et al, “Simplified low-cost production of 0-antigen from [cited by applicant]
Micoli et al, “A scalable method for 0-antigen purification applied to various [cited by applicant]
Morrison et al., Combinatorial alanine-scanning, Curr. Opin. Chem. Biol. 5: 302-307, 2001. [cited by applicant]
Nash et al., “Genome sequence of adherent-invasive [cited by applicant]
O'Brien et al, “A mucosal imprint left by prior [cited by applicant]
Pawlowski et al, “Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies,” Vaccine, vol. 18, No. 18, pp. 1873-1885 (2000). [cited by applicant]
Pearl Magala et al: “RMSD analysis of structures of the bacterial protein FimH identifies five conformations of its lectin domain”, Proteins: Structure, Function, and Bioinformatics, vol. 88, No. 4, Oct. 17, 2019 (Oct. … [cited by applicant]
Petrovsky et al, “AdvaxTM, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety,” Vaccine, vol. 33. pp. 5920-5926 (2015). [cited by applicant]
R. Stenutz et al., “The structures of [cited by applicant]
Rabbani et al, “Expression of the carbohydrate recognition domain of FimH and development of a competitive binding assay,” Analytical Biochemistry, vol. 407, pp. 188-195 (2010). [cited by applicant]
Raetz et al, “Lipopolysaccharide Endotoxins,” Annual Review of Biochemistry, vol. 71, pp. 635-700 (2002). [cited by applicant]
Raetz, “Bacterial Endotoxins: Extraordinary Lipids That Activate Eucaryotic Signal Transduction,” Journal of Bacteriology, vol. 175, No. 18, pp. 5745-5753 (1993). [cited by applicant]
Reed et al, “Key roles of adjuvants in modern vaccines,” Nature Medicine, vol. 19, No. 12, pp. 1597-1608 (2013). [cited by applicant]
Reed et al, “The science of vaccine adjuvants: advances in TLR4 ligand adjuvants,” Current Opinion in Immunology, vol. 41, pp. 85-90 (2016). [cited by applicant]
Robbins et al, “Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific bligosaccharide-core-protein conjugates,” Proceedings of the National Academy of Sciences of the United States of Ame… [cited by applicant]
Rodriquez et al. 2013 (Allosteric Coupling in the Bacterial Adhesive Protein FimH; J of Biol Chem 288(33): 24128-24139 (Year: 2013). [cited by applicant]
Rondini et al, “Design of glycoconjugate vaccines against invasive African S. Typhimurium,” Infection and Immunity, vol. 83, pp. 996-1007 (2015). [cited by applicant]
Rudinger J., Characteristics of the amino acids as components of a peptide hormone sequence, In: Peptide Hormones. (Ed) JA Parsons, University Park Press, pp. 1-7, 1976. [cited by applicant]
Russo et al, “Medical and economic impact of extraintestinal infections due to [cited by applicant]
Saraswat et al, “Preparative Purification of Recombinant Proteins: Current Status and Future Trends,” BioMed Research International, Article ID No. 312709, pp. 1-18 (2013). [cited by applicant]
Sarshar et al., FimH and Anti-Adhesive Therapeutics: A Disarming Strategy Against Uropathogens, Antibiotics 9: 397: pp. 1-16, 2009. [cited by applicant]
Sauer et al, “Catch-bond mechanism of the bacterial adhesin FimH,” Nature Communications, vol. 7, Article ID No. 10738, pp. 1-13 (2016). [cited by applicant]
Schembri et al, “Identification of a 13-kDa protein associated with the polyhydroxylkanoic acid granules from [cited by applicant]
Schwartz et al, “Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 1… [cited by applicant]
Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, Trends in Biotechnology, 18: 34-39, 2000. [cited by applicant]
Stefanetti et al, “Click Chemistry Applied to the Synthesis of [cited by applicant]
Stefanetti et al, “Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines,” Vaccine, vol. 32, pp. 6122-6129 (2014). [cited by applicant]
Stefanetti et al, “Sugar-Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella 0- Antigen Glycoconjugate Vaccines,” Angewandte Chemie International Edition, vol. 54, pp. 1-6 (2015). [cited by applicant]
Stoute et al, “A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria,” The New England Journal of Medicine, vol. 336, pp. 86-91 (1997). [cited by applicant]
Ulrich, J. Terry, et al. “Monophosphoryl lipid A as an adjuvant.” Vaccine design (1995): 495-524. [cited by applicant]
Woodward et al, “In vitro bacterial polysaccharide biosynthesis: defining the functions of Wzy and Wzz,” Nature Chemical Biology, vol. 6, No. 6, pp. 418-423 (2010). [cited by applicant]
Zhu et al, “QS-21: A Potent Vaccine Adjuvant,” Natural Products Chemistry & Research, vol. 3, No. 4, p. 1000e113 (2015), pp. 1-2. [cited by applicant]
Bouchaert et al., Receptor binding studies disclose a novel class of high-affinity inhibitors of the [cited by applicant]
Chen et al., Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding, (2009) PNAS 106:52, pp. 22439-22444. [cited by applicant]
Conte et al, “Adherent-invasive [cited by applicant]